U.S. Food and Drug Administration, “Emergency Use Authorizations,” available at <https://www.fda.gov/emergency-preparednessand-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covid19euas> (last visited May 21, 2020).+(last+visited+May+21,+2020).>Google Scholar

ClinicalTrials.gov, “COVID-19,” available at <https://clinicaltrials.gov/ct2/results?cond=COVID-19 (last visited June 5, 2020).Google Scholar

Gilead Sciences, “Emergency Access to Remdesivir Outside of Clinical Trials,” available at <https://www.gilead.com/purpose/advancing-global-health/covid-19/emergency-access-to-remdesivir-outside-of-clinical-trials> (last visited May 28, 2020).+(last+visited+May+28,+2020).>Google Scholar

Green, P., “I'm happy COVID-19 patients can access experimental drugs. Too bad those of us with ALS can't,” AZ Central, May 21, 2020, available at <https://www.azcentral.com/story/opinion/op-ed/2020/05/21/covid-19-patients-have-experimental-drugs-als-patients-like-me-dont/5226684002/> (last visited May 21, 2020). (last visited May 21, 2020).' href=https://scholar.google.com/scholar?q=Green,+P.,+“I'm+happy+COVID-19+patients+can+access+experimental+drugs.+Too+bad+those+of+us+with+ALS+can't,”+AZ+Central,+May+21,+2020,+available+at++(last+visited+May+21,+2020).>Google Scholar

U.S. Food and Drug Administration, “Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments,” March 19, 2020, available at <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

Sharfstein, J., “Déjà Vu at the FDA,” The Milbank Quarterly 95, no. 2 (2017): 245–248.Google Scholar

Joffe, S. and Lynch, H. Fernandez, “Federal Right-to-Try Legislation — Threatening the FDA's Public Health Mission,” New England Journal of Medicine 378, no. 8 (2018): 695-697; Lynch, H. Fernandez, Zettler, P.J., and Sarpatwari, A., “Promoting Patient Interests in Implementing the Federal Right to Try Act,” JAMA 320, no. 9 (2018): 869–870.CrossRefGoogle Scholar

“Westerman, Gallagher, Burchett, Braun Introduce Bicameral Prescription Drug Legislation,” December 19, 2019, available at <https://westerman.house.gov/media-center/press-releases/westerman-gallagher-burchett-braun-introduce-bicameral-prescription-drug> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

“Senator Braun & colleagues introduce Promising Pathway Act for patients with serious and life-threatening illnesses,” June 4, 2020, available at <https://www.braun.senate.gov/senator-braun-colleagues-introduce-promising-pathway-act-patients-serious-and-life-threatening> (last visited June 4, 2020). The bill's full text, available at <https://www.braun.senate.gov/sites/default/files/2020-06/Promising%20Pathway%20Act_S.3872.pdf> (last visited June 5, 2020). See also a statement from Senator Braun's office describing significant changes from the proposed Conditional Approval Act, “The Promising Pathway Act: A Bill to Expedite Positive Patient Outcomes,” available at <https://www.braun.senate.gov/sites/default/files/2020-06/PPA%20Overview.pdf> (last visited June 4, 2020). Note that this overview incorrectly states that Accelerated Approval requires the use of validated surrogates; Accelerated Approval is not limited to the use of surrogate endpoints known to predict clinical benefit. (last visited June 5, 2020). See also a statement from Senator Braun's office describing significant changes from the proposed Conditional Approval Act, “The Promising Pathway Act: A Bill to Expedite Positive Patient Outcomes,” available at (last visited June 4, 2020). Note that this overview incorrectly states that Accelerated Approval requires the use of validated surrogates; Accelerated Approval is not limited to the use of surrogate endpoints known to predict clinical benefit.' href=https://scholar.google.com/scholar?q=“Senator+Braun+&+colleagues+introduce+Promising+Pathway+Act+for+patients+with+serious+and+life-threatening+illnesses,”+June+4,+2020,+available+at++(last+visited+June+4,+2020).+The+bill's+full+text,+available+at++(last+visited+June+5,+2020).+See+also+a+statement+from+Senator+Braun's+office+describing+significant+changes+from+the+proposed+Conditional+Approval+Act,+“The+Promising+Pathway+Act:+A+Bill+to+Expedite+Positive+Patient+Outcomes,”+available+at++(last+visited+June+4,+2020).+Note+that+this+overview+incorrectly+states+that+Accelerated+Approval+requires+the+use+of+validated+surrogates;+Accelerated+Approval+is+not+limited+to+the+use+of+surrogate+endpoints+known+to+predict+clinical+benefit.>Google Scholar

I Am ALS, “Press Release: Early Access to Promising Treatments Provides New Hope in Fight,” May 28, 2020, available at <https://iamals.org/news/early-access-to-promising-treatments-provides-new-hope-in-fight-againstals-terminal-diseases/> (last visited June 2, 2020).+(last+visited+June+2,+2020).>Google Scholar

21 U.S. Code §355 (2018).Google Scholar

For diseases and conditions that lack even unvalidated surrogates, FDA should further clarify which intermediate clinical endpoints will suffice for Accelerated Approval.Google Scholar

Because the course of COVID-19 is relatively quick — patients either recover or die within a matter of weeks — reliance on surrogate endpoints and Accelerated Approval is not needed for drugs to treat this disease. Instead, Accelerated Approval is better suited for diseases and conditions with a longer trajectory that would require much longer trials to evaluate ultimate outcomes related to clinical benefit or irreversible morbidity and mortality.Google Scholar

21 U.S. Code §356(c) (1992).Google Scholar

Miller, F.G. and Joffe, S., “Balancing Access and Evaluation in the Approval of New Cancer Drugs,” JAMA 305, no. 2 (2011): 2345–2346; Herder, M., “Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency,” The Mil-bank Quarterly 97, no. 3 (2019): 820–857; DiMagno, S.S.P., and Glickman, A., Emanuel, E.J., “Accelerated Approval of Cancer Drugs — Righting the Ship of the US Food and Drug Administration,” JAMA Internal Medicine 179, no. 7 (2019): 922-923.CrossRefGoogle Scholar

Banzi, R. et al., “Conditional Approval of Medicines by the EMA,” BMJ 357 (2017), available at <https://www.bmj.com/content/357/bmj.j2062> (last visited June 5, 2020); Hoekman, J. et al., “Use of the Conditional Marketing Authorization Pathway for Oncology Medicines in Europe,” Clinical Pharmacology and Therapeutics 98, no. 5 (2015): 534–541.Google Scholar

Beaver, J.A. et al., “A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review,” JAMA Oncology 4, no. 6 (2018): 849–856; Naci, H., Smalley, K.R., and Kesselheim, A.S., “Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration,” JAMA 318, no. 7 (2017): 626–636; Herper, M., “FDA Continues to Struggle with Implications of Approving Sarepta's Drugs,” STAT, January 22, 2020, available at <https://www.statnews.com/2020/01/22/the-fda-continues-to-struggle-with-the-implications-of-approving-sareptas-drugs/> (last visited April 17, 2020).Google Scholar

Beaver et al., supra note 17; Gyawali, B., Hey, S.P., Kesselheim, A.S., “Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval,” JAMA Internal Medicine 179, no. 7 (2019): 906–913.CrossRefGoogle Scholar

Rubin, R., “Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?” JAMA 323, no. 13 (2020): 1229-1232.CrossRefGoogle Scholar

Naci, Smalley, and Kesselheim, supra note 17.Google Scholar

Vitry, A., Nguyen, T., Entwistle, V., and Roughead, E., “Regulatory Withdrawal of Medicines Marketed with Uncertain Benefits: The Bevacizumab Case Study,” Journal of Pharmaceutical Policy and Practice 8 (2015), article 25, available at <https://joppp.biomed-central.com/articles/10.1186/s40545-015-0046-2> (last visited June 5, 2020).CrossRefGoogle Scholar

Gyawali, B. and Kesselheim, A.S., “Reinforcing the Social Compromise of Accelerated Approval,” Nature Reviews Clinical Oncology 15, no. 10 (2018): 596–597.Google Scholar

U.S. Food and Drug Administration, “Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics,” September 2017, available at <http://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-andbiologics> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

Wallach, J.D., Ross, J.S., and Naci, H., “The US Food and Drug Administration's Expedited Approval Programs: Evidentiary Standards, Regulatory Trade-Offs, and Potential Improvements,” Clinical Trials 15, no. 3 (2018): 219–229; Ciani, O. et al., “Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward,” Value in Health 20, no. 3 (2017): 487–495; Gyawali, B., Hey, S.P., and Kesselheim, A.S., “Evaluating the Evidence Behind the Surrogate Measures Included in FDA's Table of Surrogate Endpoints as Supporting Approval of Cancer Drugs,” eClinical Medicine (2020), available at <https://doi.org/10.1016/j.eclinm.2020.100332> (last visited May 13, 2020).CrossRefGoogle Scholar

Piller, C., “Former FDA Leaders Decry Emergency Authorization of Malaria Drugs for Coronavirus,” Science, April 7, 2020, available at <https://www.sciencemag.org/news/2020/04/former-fda-leaders-decry-emergency-authorization-malaria-drugs-coronavirus> (last visited April 17, 2020).CrossRef+(last+visited+April+17,+2020).>Google Scholar

Miller and Joffe, supra note 15; Mello, M.M. and Brennan, T.A., “The Controversy Over High-Dose Chemotherapy with Autologous Bone Marrow Transplant for Breast Cancer,” Health Affairs 20, no. 5 (2001): 101–117.CrossRefGoogle Scholar

Herper, supra note 13.Google Scholar

Mahendraratnam, N. et al., Duke Margolis Center for Health Policy, “Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness,” December 19, 2019, available at <https://healthpolicy.duke.edu/sites/default/files/u31/adding_real-world_evidence_to_a_totality_of_evidence_approach_for_evaluating_marketed_product_effectiveness_0.pdf> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

Miller, F.G. and Joffe, S., “Equipoise and the Dilemma of Randomized Clinical Trials,” New England Journal of Medicine 364, no. 5 (2011): 476–480; Druker, B.J. et al., “Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia,” New England Journal of Medicine 344, no. 14 (2001): 1031–1037; Elliott, M.J. et al., “Treatment of Rheumatoid Arthritis with Chime-ric Monoclonal Antibodies to Tumor Necrosis Factor Alpha,” Arthritis and Rheumatism 36, no. 12 (1993): 1681–1690.CrossRefGoogle Scholar

Naci, Smalley, and Kesselheim, supra note 13; Wallach, Ross, and Naci, supra note 19; 22; Darrow, J.J., Avorn, J., and Kesselheim, A.S., “FDA Approval and Regulation of Pharmaceuticals, 1983-2018,” JAMA 323, no. 2 (2020): 164–176; Zhang, A.D. et al., “Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017,” JAMA Network Open 3, no. 4 (2020): e203284.Google Scholar

Id.Google Scholar

Thomas, K., “Insurers Battle Families Over Costly Drug for Fatal Disease,” New York Times, June 22, 2017, available at <https://www.nytimes.com/2017/06/22/health/duchenne-muscular-dystrophy-drug-exondys-51.html> (last visited June 3, 2020).+(last+visited+June+3,+2020).>Google Scholar

Kapczynski, A., “Dangerous Times: The FDA's Role in Information Production, Past and Future,” Minnesota Law Review 102 (2018): 2357–2382.Google Scholar

U.S. Food and Drug Administration, “Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use — Questions and Answers,” October 2017, available at <https://www.fda.gov/media/85675/download> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

U.S. Food and Drug Administration, “Expanded Access Program Report,” May 2018, available at <https://www.fda.gov/media/119971/download> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

O'Day, D., “An Open Letter from Our Chairman and CEO,” March 28, 2020, available at <https://www.gilead.com/stories/articles/an-open-letter-from-our-chairman-and-ceo> (last visited April 17, 2020)(acknowledging that as of the end of March 2020, Gilead had provided remdesivir to more than 1,000 COVID-19 patients through “compassionate use” programs). (last visited April 17, 2020)(acknowledging that as of the end of March 2020, Gilead had provided remdesivir to more than 1,000 COVID-19 patients through “compassionate use” programs).' href=https://scholar.google.com/scholar?q=O'Day,+D.,+“An+Open+Letter+from+Our+Chairman+and+CEO,”+March+28,+2020,+available+at++(last+visited+April+17,+2020)(acknowledging+that+as+of+the+end+of+March+2020,+Gilead+had+provided+remdesivir+to+more+than+1,000+COVID-19+patients+through+“compassionate+use”+programs).>Google Scholar

U.S. Food and Drug Administration, “Project Facilitate,” January 23, 2020, available at <https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

21 U.S. Code §60bbb-0 (2017).Google Scholar

U.S. Food and Drug Administration, “Why Does FDA Review Adverse Event Data for Expanded Access INDs?” available at <https://www.fda.gov/news-events/expanded-access/expanded-access-information-industry#FDAPolicy> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar

Larger companies are typically able to cover these costs, although even they may be overwhelmed by logistics in the event of high request volume, as we have seen during the COVID-19 pandemic. O'Day, supra note 36.Google Scholar

Folkers, K. M., Bateman-House, A., and Robertson, C., “Paying for Unapproved Medical Products,” Wake Forest Journal of Law & Public Policy (forthcoming 2020).Google Scholar

H.R. 7071, 2020, available at <https://iamals.org/wp-content/uploads/2020/06/Accelerating-Access-to-Critical-Therapies-for-ALSAct.pdf?utm_source=Social&utm_medium=Twitter&utm_campaign=ACT%20for%20ALS%20Bill> (last visited June 3, 2020); “Quigley, Fortenberry Create New Pathways for Treatment in Fight Against ALS, Neurodegenerative Diseases,” June 1, 2020, available at <https://quigley.house.gov/media-center/press-releases/quigley-fortenberry-create-new-pathways-treatment-fight-against-als> (last visited June 2, 2020). This bill would also create a Center of Excellence for Neurodegenerative Diseases at FDA, modeled after the Center of Excellence in Oncology.+(last+visited+June+3,+2020);+“Quigley,+Fortenberry+Create+New+Pathways+for+Treatment+in+Fight+Against+ALS,+Neurodegenerative+Diseases,”+June+1,+2020,+available+at++(last+visited+June+2,+2020).+This+bill+would+also+create+a+Center+of+Excellence+for+Neurodegenerative+Diseases+at+FDA,+modeled+after+the+Center+of+Excellence+in+Oncology.>Google Scholar

Joffe and Fernandez Lynch, supra note 7; Fernandez Lynch, Zettler, and Sarpatwari, supra note 7.Google Scholar

U.S. Food and Drug Administration, “Draft Guidance: Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs,” June 2019, available at <https://www.fda.gov/media/127712/download> (last visited April 17, 2020).+(last+visited+April+17,+2020).>Google Scholar